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>l-yr (cohort 3) ACV prophytaxis prevented 44% 
and 35%, respectivety, of art potentiat cases of VZV 
disease. The 2-yr probabitity of 1st episode of VZV 
disease was 26%, 8% and 4% in cohort 1, 2 and 3 
respectivety (cohort 28:3 vs cohort 1, p <0.001, 
cohort 2 vs cohort 3, p=0.02). Art VZV cases re- 
sponded to treatment with ACV or VACV. During 
the study period, 10 episodes of ACV-resistant HSV 
were documented in cohort 1 and 2 episodes in 
cohorts 2 (p = 0.002). 
Conclusions: Long-term suppressive ACV prophy- 
taxis significantty reduces the incidence of VZV 
disease during the 1st yr after HCT with no de- 
tectabte rebound disease after discontinuation of 
prophytaxis. 
Continuation of ACV beyond 1 yr in patients on 
immunosuppressive drugs may further decrease 
the risk of VZV disease. Suppressive acyctovir use 
strongty reduces the risk of ACV-resistant HSV in- 
fection. 
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Background: In immunotogicatty normat hosts, par- 
vovirus B19 virus can cause, acute, generatty serf- 
timiting diseases, whereas in immunocompromised 
hosts, the infection can persist, reading to chronic 
anemia, red cett aptasia, thrombocytopenia, neu- 
tropenia and even pancytopenia. Chitdren are 
probabty at highest risk, since they may not yet 
have encountered the infection in rife and thus tack 
immunity. The ctinicat and hemathotogicat picture 
of a parvovirus B19 infection may mimic a teukemic 
retapse or therapy-induced cytopenia. 
Objectives: The aim of this study is; to investigate 
parvovirus B19 infections in pediatric sotid-organ 
and bone marrow transptant recipients and sotid 
tumor patients by serotogicat and motecutar meth- 
ods and investigate their ctinicat benefit during one 
year period. 
Methods: One hundred and seven ptasma samptes 
from 28 chitdren with sotid tumor or who have 
sotid-organ or bone marrow transptantation in Ak- 
deniz University Medicat Facutty, Antatya, Turkey, 
were corrected on a monthty basis for a year. Mi- 
cro ELISA based method were used to detect Par- 
vovirus B19 IgM (Novum Diagnostica, Dietzenbach, 
Germany) and IgG (Focus Diagnostics, Catifornia, 
USA) antibodies. Parvovirus B19 DNA was detected 
with LightCycter-parvovirus B19 quantification kit 
(Roche, Mannheim, Germany). An in-house PCR 
method was atso used for Parvovirus B19 DNA de- 
tection. 
Results: Sixteen patients were positive for Par- 
vovirus B19 IgG antibodies. One patient was pos- 
itive for Parvovirus IgG and IgM antibodies. For an- 
other patient onty Parvovirus IgM antibodies were 
positive. Incoconsistent parvovirus B19 IgG test re- 
sutts were observed in consecutive ptasma samptes 
from same patients. Parvovirus B19 DNA was posi- 
tive in first samptes of five patients by LightCycter- 
parvovirus B19 quantification kit, ranging between 
250-1124 copies/mL. Fottowing samptes of these 
patients were negative. Parvovirus B19 DNA was 
negative in art samptes by in-house PCR. The pa- 
tient who has 1124copies/mL of Parvovirus B19 
DNA, had significantty reduced hemogtobin and 
hematocrit resutts and fever was noted for the 
sampting time. For the other four patients, ctinicat 
and taboratory findings were not suggestive for an 
active Parvovirus B19 infection. 
Conclusion: Sensitive rear-time PCR assays are 
mandatory for diagnosing active Parvovirus B19 in- 
fections in sotid organ and bone marrow transptant 
recipients and patients with sotid tumor especiatty 
in the chitdhood. Serotogicat methods are inade- 
quate and insensitive for this group of patients. 
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Background: The incidence and severity of CDAD 
has increased in recent years atong with the pres- 
ence of a more virutent strain. However, there are 
no recent studies rooking at the characteristics of
this infection in HSCT recipients, a poputation at 
increased risk. 
Objectives: To evatuate the incidence and charac- 
teristics of CDAD and the associated risk factors of 
this infection in patients who underwent attogeneic 
and autotogous HSCT at Henry Ford Hlospitat during 
2005. 
Methods: We performed a retrospective, un- 
matched, case-controt study from January to De- 
cember 2005. Inctusion criteria were HSCT patients 
with CDAD diagnosed by identification of C. di[- 
ficile toxin A or B in stoot by ELISA and ctinicat 
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manifestations (diarrhea, abdomina[ pain or fever). 
The contro[ popu[ation was HSCT recipients who 
did not met the inc[usion criteria during the same 
period. Data on demographics, duration of previous 
and current hospita[izations, use of antibiotics and 
chemotherapeutic agents, symptoms, treatment 
and outcome was corrected. Patients were fottowed 
up for 3 months after HSCT. A p vatue ~<0.05 was 
considered significant. 
Results: The incidence of CDAD in HSCT patients 
increased during 2005 to 34% (16 out of 47 HSCT) 
compared to the average of 10.4% from 2001 to 
2004. No difference was found between cases and 
controts in regards to age, gender, race, under- 
[ying disease or type of transp[ant. There was a 
trend towards [onger hospita[ stay 60 days prior 
to admission in patients with CDAD compared to 
contro[s (mean of 60 days vs. 13 days, p=0.06). 
No statistica[ difference was found in the use of 
antimicrobia[s during the 60 days prior to deve[- 
opment of CDAD, concomitant GVHD, duration of 
neutropenia or associated infections inc[uding CMV. 
An interesting finding was that 13 out of 31 con- 
tro[s versus none of the CDAD patients received 
preemptive therapy with either ora[ metronidazo[e 
or vancomycin at time of deve[opment of diarrhea. 
A[[ CDAD patients had diarrhea and 81% had fever. 
They were treated with ora[ metronidazo[e and/or 
vancomycin. Four cases (25%) devetoped retapse of 
CDAD; one of them died (morta[ity 6.25%). Another 
patient died of unre[ated comp[ications. 
Conclusions: A[though the frequency of CDAD in 
our HSCT recipients has shown an increase of more 
than three-ford during 2005, we were not abte to 
identify any associated risk factors in this popu[a- 
tion; and the characteristics of the disease were 
simi[ar to cases reported in the [iterature. 
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Background: Over the past 6 years awareness of 
[ate CMV disease has increased and major changes 
in transptantation techniques have occurred with 
increased use of periphera[ brood stem cetts (PBSC) 
and non-myetoabtative (NM) conditioning. 
Objectives: To determine the impact of changes 
in transplantation techniques and extended CMV 
prevention strategies. 
Methods: 2486 patients (pts) transplanted between 
1/94 and 12/03 were studied. Gancidovir (GCV) 
or V-GCV was given for CMV AG/PCR positivity 
before day 100; after day 100, pts. received either 
preemptive therapy (PET) or V-GCV prophylaxis. 
Neutropenia was analyzed after engraftment and 
following PET. Cox regression models and cumula- 
tive incidence curves were used to estimate risk 
factors (RF) and probabilities of endpoints, respec- 
tively. 
Results: The incidence of asymptomatic CMV in- 
fection was stable throughout he study period; RF 
included age, female sex, HLA mismatched or un- 
related donor status, and acute GvHD. For CMV dis- 
ease, a decline was observed after 2000 (adj. haz- 
ard ratio [HR] 0.7, p = 0.03); this decline was mainly 
due to a decline in [ate CMV disease (adj. HR 0.57, 
p=0.04). RF for [ate CMV disease included AG/PCR 
positivity before day 100 (adj. HR 2.7, p =0.03) and 
HLA mismatched or unrelated donor status (adj. 
HR 2, P < 0.01); ceil source, donor/recipient age, 
donor CMV status, and NM conditioning regimen 
were not significant while graft versus host disease 
(GvHD) was borderline significant (adj. HR 2.5, 
p=0.06). Neutropenia following GCV/V-GCV was 
similar between NM and M-HCT recipients (ANC < 
1000, 50% vs. 39%, HR 1.4, p=0.12; ANC < 500, 31% 
vs. 17%, adj. HR 1.7, p = 0.1 ). Risk factors for severe 
GCV-N (ANC < 500) were recipient age (adj. HR 
1.2 [10yr increments], p=0.03) and chronic GvHD 
(adj. HR 1.9, p<0.01). In a mode[ that included 
the entire cohort, risk factors for severe post- 
engraftment neutropenia (ANC<500) inc[uded NM- 
HCT, BM as cet[ source, HSV serostatus, acute and 
chronic GVHD, and CMV infection. 
Conclusions: Extended prevention strategies for 
[ate CMV disease ted to a significant reduction of 
CMV disease in HCT recipients. NM-HCT was not 
associated with a reduced risk of CMV or GCV- 
re[ated neutropenia. The high susceptibi[ity for 
neutropenia in NM-HCT recipients cou[d be due 
to higher recipient age and use of mye[otoxic co- 
medications (e.g. MMF, TMP-SMX) in these patients. 
